
TransMedics raises 2026 revenue guidance after Q3 revenue jumps 41% with strong growth and new FDA trial approvals
TransMedics Group reported a 41% revenue increase to $203 million in Q3 2026, driven by growth in organ transplant products and services. The company raised its full-year 2026 revenue guidance to $764-$774 million, including contributions from its ne...





